Epidemiology of Parkinson's disease.

By Lonneke M. L. de Lau, Monique M. B. Breteler. Lancet Neurology, 2006

2,658 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases (2015, background): “The mean age of onset is around 60 years, although 5–10% of cases, classified as young onset, begin between the ages of 20 and 50 (de Lau & Breteler, 2006).”
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action (2010, background): “problem in our aging societies, primarily as there is an increased prevalence of both Alzheimer’s disease [174,175] and Parkinson’s disease [175-177] with age.”
The clinical symptoms of Parkinson's disease (2016, background): “The prevalence of PD in industrialised countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (De Lau and Breteler 2006).”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “The incidence rate of PD is 8–18 individuals per 100,000 person-years (Tanner and Goldman 1996; Nussbaum and Ellis 2003; de Lau and Breteler 2006).”
Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson’s disease (2019, background): “For each OR in the interval [1, 10] at steps of 0.”